Company news

Ascendis Pharma A/S news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 13, 2025

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 12, 2025

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 5, 2025

Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

March 30, 2025

First and only treatment for chronic hypoparathyroidism approved in Australia

February 19, 2025

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

February 11, 2025

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

December 18, 2024

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

December 11, 2024

← Newer news releases

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 30 decks. Every deck is listed under its year.